T&R Biofab Co., Ltd.
KOSDAQTotal Valuation
T&R Biofab Co., Ltd. carries a market capitalization of 50.10B, placing it among publicly traded companies globally. Its enterprise value stands at 111.61B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 50.10B |
| Enterprise Value | 111.61B |
Valuation Ratios
The price-to-sales ratio is 2.99, and the price-to-book ratio stands at -0.59.
| PE Ratio | N/A |
| PS Ratio | 2.99 |
| PB Ratio | -0.59 |
| P/TBV Ratio | 4.37 |
| P/FCF Ratio | 193.02 |
| P/OCF Ratio | -38.53 |
Enterprise Valuation
| EV / Sales | 3.75 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 17.05 |
Financial Position
T&R Biofab Co., Ltd. maintains a current ratio of 1.03, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 140.70, indicating elevated leverage, while an interest coverage ratio of -0.98 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.03 |
| Quick Ratio | 0.42 |
| Debt / Equity | 140.70 |
| Debt / EBITDA | -5.07 |
| Interest Coverage | -0.98 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -33.55 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 5.45 |
Stock Price Statistics
T&R Biofab Co., Ltd.'s stock has declined approximately -53.0777% over the past 52 weeks. The 50-day moving average sits at 2,384.50, while the 200-day moving average is 2,632.50.
| Beta (5Y) | N/A |
| 52-Week Price Change | -53.0777% |
| 50-Day Moving Average | 2,384.50 |
| 200-Day Moving Average | 2,632.50 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, T&R Biofab Co., Ltd. generated 29.73B in revenue and converted that into -31.21B in net income, yielding earnings per share of -948.24. EBITDA reached -5.94B, while operating income came in at -5.94B.
| Revenue | 29.73B |
| Gross Profit | 8.60B |
| Operating Income | -5.94B |
| Pretax Income | -31.21B |
| Net Income | -31.21B |
| EBITDA | -5.94B |
| EBIT | -5.94B |
| Earnings Per Share (EPS) | -948.24 |
Balance Sheet
T&R Biofab Co., Ltd. holds 7.40B in cash and equivalents against 30.13B in total debt, resulting in a net debt position of 21.91B. Total book value stands at -150.90B, with working capital of 467.22M providing operational flexibility.
| Cash & Cash Equivalents | 7.40B |
| Total Debt | 30.13B |
| Net Debt | 21.91B |
| Equity (Book Value) | -150.90B |
| Book Value Per Share | -4,584.30 |
| Working Capital | 467.22M |
Cash Flow
T&R Biofab Co., Ltd. produced -2.31B in operating cash flow over the past twelve months. After subtracting -2.77B in capital expenditures, free cash flow totaled -5.07B - equivalent to -154.14 per share.
| Operating Cash Flow | -2.31B |
| Capital Expenditures | -2.77B |
| Free Cash Flow | -5.07B |
| FCF Per Share | -154.14 |
Margins
T&R Biofab Co., Ltd. operates with a gross margin of 28.91, reflecting its pricing power and cost economics. The operating margin of -19.99 and net profit margin of -104.97 provide insight into operational efficiency.
| Gross Margin | 28.91 |
| Operating Margin | -19.99 |
| Pretax Margin | -104.97 |
| Profit Margin | -104.97 |
| EBITDA Margin | -19.99 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 3.54 |
| FCF Yield | 0.52 |
Stock Splits
T&R Biofab Co., Ltd.'s most recent stock split took place on April 5, 2022 with a 1:2 split ratio.
| Last Split Date | 4/5/2022 |
| Split Ratio | 1:2 |
Scores
T&R Biofab Co., Ltd. posts an Altman Z-Score of -1.81, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -1.81 |